Home » Stocks » Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc. (SPPI)

Stock Price: $3.93 USD 0.08 (2.08%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $4.00 +0.07 (1.78%) Aug 10, 7:59 PM

Stock Price Chart

Key Info

Market Cap 451.16M
Revenue (ttm) 109.33M
Net Income (ttm) -134.11M
Shares Out 142.09M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $3.93
Previous Close $3.85
Change ($) 0.08
Change (%) 2.08%
Day's Open 3.90
Day's Range 3.70 - 4.02
Day's Volume 1,994,798
52-Week Range 1.74 - 10.57

More Stats

Market Cap 451.16M
Enterprise Value 273.37M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 142.09M
Float 109.89M
EPS (basic) -1.2
EPS (diluted) -1.21
FCF / Share -1.23
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.51M
Short Ratio 4.44
Short % of Float 7.82%
Beta 2.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.13
PB Ratio 3.61
Revenue 109.33M
Operating Income -133.65M
Net Income -134.11M
Free Cash Flow -137.97M
Net Cash 177.79M
Net Cash / Share 1.55
Gross Margin n/a
Operating Margin -122.24%
Profit Margin n/a
FCF Margin -126.19%
ROA -29.88%
ROE -63.88%
ROIC -110.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$10.25*
(160.81% upside)
Low
7.00
Current: $3.93
High
13.00
Target: 10.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue---14616318715626819374.11
Revenue Growth----9.91%-12.99%19.88%-41.78%38.73%160.36%-
Gross Profit---11113516012722115956.67
Operating Income-141-138-116-62.89-42.59-31.57-38.7980.7756.55-51.12
Net Income-113-121-92.19-69.77-52.64-45.72-62.1394.2049.93-47.06
Shares Outstanding11110385.1272.8264.8864.7160.7358.5953.2749.50
Earnings Per Share-1.02-1.17-1.08-0.96-0.81-0.71-1.021.460.86-0.95
EPS Growth-------69.77%--
Operating Cash Flow-135-62.40-38.86-40.466.74-3.63-2.0971.9643.29-22.54
Capital Expenditures-8.97-0.11-0.47-0.08-0.22-25.93-0.16-0.31-0.48-1.58
Free Cash Flow-144-62.51-39.32-40.546.52-29.56-2.2571.6542.81-24.12
Cash & Equivalents22420422815814013316014316195.67
Total Debt--38.2297.0499.3896.3091.4875.000.010.04
Net Cash / Debt22420418961.4340.6136.9568.3068.0116195.63
Assets263391487429419490499505281164
Liabilities73.0411913619320623521821688.6989.16
Book Value19027135123621325528228919274.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Spectrum Pharmaceuticals, Inc.
Country United States
Employees 146
CEO Joseph W. Turgeon

Stock Information

Ticker Symbol SPPI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SPPI
IPO Date September 26, 1996

Description

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.